Pathophysiological relevance of NO signaling in the cardiovascular system: Novel insight from mice lacking all NO synthases

Pharmacology and Therapeutics

Volumn 128, Issue 3, 2010, Pages 499-508

  Tsutsui, Masato ^a   Shimokawa, Hiroaki ^b   Otsuji, Yutaka ^c   Yanagihara, Nobuyuki ^c  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cardiovascular disease; Knockout mice; Lipid metabolism; Myocardial infarction; Nitric oxide; Nitric oxide synthase

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDRALAZINE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NICORANDIL; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; OLMESARTAN; TRIACYLGLYCEROL;

ANGINA PECTORIS; ARTERIOSCLEROSIS; ARTERY DIAMETER; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DIETARY INTAKE; DYSLIPIDEMIA; ENZYME SYNTHESIS; GENE DISRUPTION; GENETIC MODEL; GLUCOSE METABOLISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART VENTRICLE OVERLOAD; HUMAN; HYPERPOLARIZATION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STABLE ANGINA PECTORIS; SUDDEN DEATH; TRANSGENIC MOUSE; VASCULAR LESION;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION;

EID: 78049280211     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.08.010     Document Type: Review

References (81)

1. Antman E.M., Braunwald E. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. Braunwald's Heart Disease 2005, 1141-1166. Elsevier Saunders, Philadelphia. 7th edition. D.P. Zipes, P. Libby, R.O. Bonow, E. Braunwald (Eds.).
2. Boulanger C.M., Heymes C., Benessiano J., Geske R.S., Levy B.I., Vanhoutte P.M. Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. Circ Res 1998, 83(12):1271-1278.
3. Bredt D.S., Snyder S.H. Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 1994, 63:175-195.
4. Brunner F., Andrew P., Wolkart G., Zechner R., Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001, 104(25):3097-3102.
5. Buchwalow I.B., Podzuweit T., Bocker W., Samoilova V.E., Thomas S., Wellner M., et al. Vascular smooth muscle and nitric oxide synthase. FASEB J 2002, 16(6):500-508.
6. Burkard N., Rokita A.G., Kaufmann S.G., Hallhuber M., Wu R., Hu K., et al. Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 2007, 100(3):e32-e44.
7. Bussmann W.D., Passek D., Seidel W., Kaltenbach M. Reduction of CK and CK-MB indexes of infarct size by intravenous nitroglycerin. Circulation 1981, 63(3):615-622.
8. Cook S. Coronary artery disease, nitric oxide and oxidative stress: the "Yin-Yang" effect, a Chinese concept for a worldwide pandemic. Swiss Med Wkly 2006, 136(7-8):103-113.
9. Cooke J.P. ADMA: its role in vascular disease. Vasc Med 2005, 10(Suppl 1):S11-S17.
10. Daiber A., Wenzel P., Oelze M., Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2008, 97(1):12-20.
11. Dzau V.J., Bernstein K., Celermajer D., Cohen J., Dahlof B., Deanfield J., et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002, 16(2):149-160.
12. Ebrahimian T., Mathieu E., Silvestre J.S., Boulanger C.M. Intraluminal pressure increases vascular neuronal nitric oxide synthase expression. J Hypertens 2003, 21(5):937-942.
13. Ernsberger P., Koletsky R.J. Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol 2006, 373(4):245-258.
14. Furchgott R.F. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 1984, 24:175-197.
15. Godecke A., Decking U.K., Ding Z., Hirchenhain J., Bidmon H.J., Godecke S., et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res 1998, 82(2):186-194.
16. Gyurko R., Leupen S., Huang P.L. Deletion of exon 6 of the neuronal nitric oxide synthase gene in mice results in hypogonadism and infertility. Endocrinology 2002, 143(7):2767-2774.
17. Heger J., Godecke A., Flogel U., Merx M.W., Molojavyi A., Kuhn-Velten W.N., et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002, 90(1):93-99.
18. Hirohata A., Yamamoto K., Miyoshi T., Hatanaka K., Hirohata S., Yamawaki H., et al. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol 2010, 55(10):976-982.
19. Hua X., Yokoyama C., Wu J., Briggs M.R., Brown M.S., Goldstein J.L., et al. SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A 1993, 90(24):11603-11607.
20. Huang P.L., Dawson T.M., Bredt D.S., Snyder S.H., Fishman M.C. Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993, 75(7):1273-1286.
21. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377:239-242.
22. Huang A., Sun D., Shesely E.G., Levee E.M., Koller A., Kaley G. Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol Heart Circ Physiol 2002, 282(2):H429-H436.
23. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990, 30:535-560.
24. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002, 359(9314):1269-1275.
25. Ishikawa K., Kanamasa K., Ogawa I., Takenaka T., Naito T., Kamata N., et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996, 60(10):779-788.
26. Janssens S., Pokreisz P., Schoonjans L., Pellens M., Vermeersch P., Tjwa M., et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004, 94(9):1256-1262.
27. Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988, 78(4):906-919.
28. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116(7):1784-1792.
29. Kanamasa K., Hayashi T., Takenaka T., Kimura A., Ikeda A., Ishikawa K. Chronic use of continuous dosing of long-term nitrates does not prevent cardiac events in patients with severe acute myocardial infarction. Cardiology 2000, 94(3):139-145.
30. Kuhlencordt P.J., Hotten S., Schodel J., Rutzel S., Hu K., Widder J., et al. Atheroprotective effects of neuronal nitric oxide synthase in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2006, 26(7):1539-1544.
31. Kurioka S., Koshimura K., Murakami Y., Nishiki M., Kato Y. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 2000, 47(1):77-81.
32. Laine P., Kaartinen M., Penttila A., Panula P., Paavonen T., Kovanen P.T. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 1999, 99(3):361-369.
33. Lamping K.G., Nuno D.W., Shesely E.G., Maeda N., Faraci F.M. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol 2000, 279(4):H1906-H1912.
34. Laubach V.E., Shesely E.G., Smithies O., Sherman P.A. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A 1995, 92(23):10688-10692.
35. Libby P. The vascular biology of atherosclerosis. Braunwald's Heart Disease 2008, 985-1002. Saunders Elsevier, Philadelphia. P. Libby, R. Bonow, D. Mann, D. Zipes (Eds.).
36. Loyer X., Gomez A.M., Milliez P., Fernandez-Velasco M., Vangheluwe P., Vinet L., et al. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 2008, 117(25):3187-3198.
37. MacMicking J.D., Nathan C., Hom G., Chartrain N., Fletcher D.S., Trumbauer M., et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995, 81(4):641-650.
38. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24(1):29-33.
39. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
40. Morishita T., Tsutsui M., Shimokawa H., Horiuchi M., Tanimoto A., Suda O., et al. Vasculoprotective roles of neuronal nitric oxide synthase. FASEB J 2002, 16(14):1994-1996.
41. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 2005, 102(30):10616-10621.
42. Moroi M., Zhang L., Yasuda T., Virmani R., Gold H.K., Fishman M.C., et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998, 101(6):1225-1232.
43. Mungrue I.N., Gros R., You X., Pirani A., Azad A., Csont T., et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002, 109(6):735-743.
44. Mungrue I.N., Husain M., Stewart D.J. The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev 2002, 7(4):407-422.
45. Murad F. What are the molecular mechanisms for the antiproliferative effects of nitric oxide and cGMP in vascular smooth muscle?. Circulation 1997, 95(5):1101-1103.
46. Nakamura T., Tsubono Y., Kameda-Takemura K., Funahashi T., Yamashita S., Hisamichi S., et al. Magnitude of sustained multiple risk factors for ischemic heart disease in Japanese employees: a case-control study. Jpn Circ J 2001, 65(1):11-17.
47. Nakata S., Tsutsui M., Shimokawa H., Suda O., Morishita T., Shibata K., et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008, 117(17):2211-2223.
48. Nakata S., Tsutsui M., Shimokawa H., Tamura M., Tasaki H., Morishita T., et al. Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth factor. Arterioscler Thromb Vasc Biol 2005.
49. Nakata S., Tsutsui M., Shimokawa H., Yamashita T., Tanimoto A., Tasaki H., et al. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway. Arterioscler Thromb Vasc Biol 2007, 27(1):92-98.
50. Node K., Kitakaze M., Yoshikawa H., Kosaka H., Hori M. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension 1997, 30(3 Pt 1):405-408.
51. Ohashi Y., Kawashima S., Hirata K., Yamashita T., Ishida T., Inoue N., et al. Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J Clin Invest 1998, 102(12):2061-2071.
52. Ortiz P.A., Garvin J.L. Cardiovascular and renal control in NOS-deficient mouse models. Am J Physiol Regul Integr Comp Physiol 2003, 284(3):R628-R638.
53. Pabla R., Curtis M.J. Effects of NO modulation on cardiac arrhythmias in the rat isolated heart. Circ Res 1995, 77(5):984-992.
54. Pabla R., Curtis M.J. Endogenous protection against reperfusion-induced ventricular fibrillation: role of neuronal versus non-neuronal sources of nitric oxide and species dependence in the rat versus rabbit isolated heart. J Mol Cell Cardiol 1996, 28(10):2097-2110.
55. Packer M.A., Hemish J., Mignone J.L., John S., Pugach I., Enikolopov G. Transgenic mice overexpressing nNOS in the adult nervous system. Cell Mol Biol (Noisy-le-grand) 2005, 51(3):269-277.
56. Park C.S., Park R., Krishna G. Constitutive expression and structural diversity of inducible isoform of nitric oxide synthase in human tissues. Life Sci 1996, 59(3):219-225.
57. Piatti P., Di Mario C., Monti L.D., Fragasso G., Sgura F., Caumo A., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation 2003, 108(17):2074-2081.
58. Rapaport E. Influence of long-acting nitrate therapy on the risk of reinfarction, sudden death, and total mortality in survivors of acute myocardial infarction. Am Heart J 1985, 110(1 Pt 2):276-280.
59. Sabanai K., Tsutsui M., Sakai A., Hirasawa H., Tanaka S., Nakamura E., et al. Genetic disruption of all nitric oxide synthase isoforms enhances bone mineral density and bone turnover in mice in vivo: Involvement of the renin-angiotensin system. J Bone Miner Res 2008, 23(5):633-643.
60. Shesely E.G., Maeda N., Kim H.S., Desai K.M., Krege J.H., Laubach V.E., et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996, 93(23):13176-13181.
61. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol 1999, 31:23-37.
62. Shioji K., Moriwaki S., Takeuchi Y., Uegaito T., Mutsuo S., Matsuda M. Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. Circ J 2007, 71(5):675-680.
63. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361(9359):777-780.
64. Son H., Hawkins R.D., Martin K., Kiebler M., Huang P.L., Fishman M.C., et al. Long-term potentiation is reduced in mice that are doubly mutant in endothelial and neuronal nitric oxide synthase. Cell 1996, 87(6):1015-1023.
65. Suda O., Tsutsui M., Morishita T., Tanimoto A., Horiuchi M., Tasaki H., et al. Long-term treatment with N(omega)-nitro-l-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002, 106(13):1729-1735.
66. Suda O., Tsutsui M., Morishita T., Tasaki H., Ueno S., Nakata S., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice. Arterioscler Thromb Vasc Biol 2004, 24(9):1682-1688.
67. Takaki A., Morikawa K., Tsutsui M., Murayama Y., Tekes E., Yamagishi H., et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 2008, 205(9):2053-2063.
68. Takamura T., Kato I., Kimura N., Nakazawa T., Yonekura H., Takasawa S., et al. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J Biol Chem 1998, 273(5):2493-2496.
69. Takeno M., Yasuda S., Otsuka Y., Morii I., Kawamura A., Yano K., et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein. Circ J 2008, 72(3):415-419.
70. Tanaka S., Yashiro A., Nakashima Y., Nanri H., Ikeda M., Kuroiwa A. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 1997, 20(4):361-365.
71. Tranguch S., Huet-Hudson Y. Decreased viability of nitric oxide synthase double knockout mice. Mol Reprod Dev 2003, 65(2):175-179.
72. Tsutsui M. Neuronal nitric oxide synthase as a novel anti-atherogenic factor. J Atheroscler Thromb 2004, 11(2):41-48.
73. Tsutsui M., Nakata S., Shimokawa H., Otsuji Y., Yanagihara N. Spontaneous myocardial infarction and nitric oxide synthase. Trends Cardiovasc Med 2008, 18(8):275-279.
74. Tsutsui M., Shimokawa H., Otsuji Y., Ueta Y., Sasaguri Y., Yanagihara N. Nitric oxide synthases and cardiovascular diseases: insights from genetically modified mice. Circ J 2009, 73(6):986-993.
75. van Haperen R., de Waard M., van Deel E., Mees B., Kutryk M., van Aken T., et al. Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 2002, 277(50):48803-48807.
76. Vanhoutte P.M., Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation 1989, 80(1):1-9.
77. Ward M.E., Toporsian M., Scott J.A., Teoh H., Govindaraju V., Quan A., et al. Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant. J Clin Invest 2005, 115(11):3128-3139.
78. Wei X.Q., Charles I.G., Smith A., Ure J., Feng G.J., Huang F.P., et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995, 375(6530):408-411.
79. Wilcox J.N., Subramanian R.R., Sundell C.L., Tracey W.R., Pollock J.S., Harrison D.G., et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997, 17(11):2479-2488.
80. Yatera Y., Shibata K., Furuno Y., Sabanai K., Morisada N., Nakata S., et al. Severe dyslipidemia, atherosclerosis, and sudden cardiac death in mice lacking all NO synthases fed a high-fat diet. Cardiovasc Res 2010, 87:675-682.
81. Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372(9644):1174-1183.